Sacituzumab Govitecan Generates Responses With Manageable Safety Profile in ES-SCLC
Sacituzumab govitecan (Trodelvy) demonstrated antitumor activity in extensive-stage small cell lung cancer (ES-SCLC) patients, with an overall response rate of 41.9% and a disease control rate of 83.7%. The treatment showed efficacy in both platinum-resistant and -sensitive disease subgroups, with a safety profile consistent with previous studies. These findings support further investigation in a randomized phase 3 trial.
Related Clinical Trials
Reference News
Sacituzumab govitecan (Trodelvy) demonstrated antitumor activity in extensive-stage small cell lung cancer (ES-SCLC) patients, with an overall response rate of 41.9% and a disease control rate of 83.7%. The treatment showed efficacy in both platinum-resistant and -sensitive disease subgroups, with a safety profile consistent with previous studies. These findings support further investigation in a randomized phase 3 trial.